Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. Co.'s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. We show 17 historical shares outstanding datapoints in our coverage of LRMR's shares outstanding history.
Understanding the changing numbers of LRMR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like LRMR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching LRMR by allowing them to research LRMR shares outstanding history
as well as any other stock in our coverage universe. |
Free LRMR Email Alerts:
Video: Shares Outstanding Importance
